Bank of America
BLACR

Bank of America’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Bank of America’s Portfolio BLACR Stock Details BLACR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$11 – 8683
2024
Q4 		$11 Hold
100
– – ﹤0.01% 8089
2024
Q3 		$10 Hold
100
– – ﹤0.01% 8051
2024
Q2 		$10 Hold
100
– – ﹤0.01% 8090
2024
Q1 		$14 Hold
100
– – ﹤0.01% 7521
2023
Q4 		$14 Hold
100
– – ﹤0.01% 7731
2023
Q3 		$23 Sell
100
-200
-67% -$39 ﹤0.01% 7564
2023
Q2 		$57 Buy
+300
New +$52 ﹤0.01% 7457

Bank of America's BLACR Position: Q1 2025 in Review

Bank of America sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 100 shares — an estimated $11 sold.

Bank of America first reported a position in BLACR in Q2 2023 and held it in 7 quarters. The position peaked at $57 in Q2 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

  • Bank of America reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
  • Bank of America sold 100 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $11.
  • Bank of America first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q2 2023 and held it in 7 quarters.
  • Bank of America's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $57 in Q2 2023.
  • 0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Bank of America's 13F filing for Q1 2025, filed 15 May 2025.